Clinical trials located in

Łódź

Łódź city is located in Poland. Currently, 2 clinical trials are being conducted in this city.

Łódź, located in central Poland, is renowned for its vibrant cultural scene and rich industrial heritage. Established in the 14th century, it became a major textile manufacturing hub in the 19th century, earning the nickname “Polish Manchester.” The city is home to the famous Piotrkowska Street, one of Europe’s longest commercial streets, bustling with cafes, shops, and art installations. Łódź also boasts the unique Museum of the Factory, highlighting its industrial past, and the impressive Manufaktura complex, a former textile factory turned cultural and shopping center. The city’s commitment to arts is evident in its numerous galleries and the National Film School, one of the oldest film schools in the world.

  • CT-EU-00114975

    Study on Ravulizumab’s effect on Immunoglobulin A Nephropathy

    The study is looking into the effectiveness of a medication called ravulizumab for adults who have a kidney condition known as Immunoglobulin A Nephropathy (IgAN). This condition can lead to kidney damage over time, and the study aims to find out if ravulizumab can help reduce the amount of protein lost in urine—a common problem in IgAN—and slow down the decrease in kidney function.

    In this study, about 450 participants who are at a high risk of their disease getting worse will be chosen. These participants must have been on stable treatment for their IgAN for at least three months before the study starts. They will then receive either ravulizumab or a placebo, which is a treatment with no active drug, through an IV infusion based on their weight. The main goal is to see if those who receive ravulizumab have a significant improvement in their condition compared to those who receive the placebo.

    The study will have two main checkpoints. The first one, at Week 34, will check how much protein is in the urine, and the second one, at Week 106, will assess how well the kidneys are filtering waste from the blood. Additionally, a smaller group of participants with more advanced kidney issues will receive ravulizumab to further explore its effects.

    After the study ends at Week 106, participants will have the option to continue receiving ravulizumab in a follow-up period to see how long-term treatment affects their condition. This study is a chance for people with IgAN to potentially slow down their disease progression and improve their quality of life.

    • placebo
    • Ravulizumab
  • Evaluating the efficacy and safety of cyclosporine and methotrexate in children with moderate to severe atopic dermatitis

    This study aims to assess how well and how safe two medicines, cyclosporine and methotrexate, are in treating children who have a skin condition known as moderate to severe atopic dermatitis. Atopic dermatitis can make the skin very itchy and red, and it’s more commonly known as eczema.

    The main goal of this research is to see if these two medicines can help children with eczema better than the treatments that are currently approved and available. Researchers want to find out if using cyclosporine and methotrexate can improve symptoms, how safe these treatments are when given to children, and if there are any differences in their effectiveness or safety. Another important aspect of this study is to see how long the improvements last after the treatment has ended.

    The findings from this study could provide new information that might help doctors and patients decide on the best ways to treat severe eczema in children in the future. The study is intended for children aged 2 to 18 years old.

    • Methotrexate
    • Cyclosporine A

See more clinical trials in other cities in Poland:

.